clinical trial · NCT06544629
Imjudo & Imfinzi PMS
AstraZeneca·—·recruiting·n = 246
Hepatocellular Carcinoma
brief summary
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea.
started
Apr 14, 2025
primary completion
Feb 28, 2029
completion
Feb 28, 2029
last updated
Nov 21, 2025
detailed description
Primary Objective:
To assess safety of the study drugs for patients treated with the study drugs under the approved indication in Korea
Secondary Objective:
To assess effectiveness of the study drugs for patients treated with the study drugs under the approved indication in Korea
Exploratory Objective:
To assess effectiveness of the study drugs for patients treated with the study drugs under the approved indication in Korea
official title
Imjudo & Imfinzi Post-Marketing Surveillance
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol